CNBC December 16, 2025
Key Points
– Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline.
– The company expects adjusted profit of $2.80 to $3 per share next year, and revenue of $59.5 billion to $62.5 billion.
– The drugmaker has pursued deals of all sizes in recent years to build new revenue streams, but the guidance underscores that those investments are still some distance from paying off.
Pfizer on Tuesday forecast modest 2026 guidance as it looks to longer-term investments in its pipeline to counter waning Covid product sales and declines from older drugs.
Those hurdles aren’t surprising or new for Pfizer, which has seen a...
Today's Sponsors
Today's Sponsor